ReviewCancer gene therapy2026
Memory programming and new manufacturing paradigms in CAR-T cell therapy.
Review in Cancer gene therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic efficacy of chimeric antigen receptor (CAR) T cells is often constrained by their limited persistence in vivo. Accordingly, numerous strategies have been developed to prolong CAR-T cell survival, many of which leverage memory-like phenotypes to sustain anti-tumor activity. However, extended persistence can also exacerbate CAR-T cell-related toxicities in certain malignancies, underscoring the need for context-specific approaches. Moreover, the rapid advancement of "off-the-shelf" CAR-T platforms may diminish the necessity for engineering enhanced persistence, enabling timely and broadly accessible therapies. In this review, we discuss recent advances aimed at augmenting CAR-T cell persistence with an emphasis on memory-associated features, and highlight emerging technologies that promise to deliver ready-to-use CAR-T products while mitigating the need for further persistence-focused modifications.
Indexed as
Identifiers
41834019What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.